Life Molecular Imaging GmbH (LMI) is a Germany-based Research and Development (R&D) organization focused on developing Positron Emission Tomography (PET) imaging solutions to diseases with high unmet medical need. As a division of the Alliance Medical Group, we are a fully integrated pharmaceutical company with research and development laboratories, access to a network of cyclotrons, radio-pharmacies and imaging facilities. Our vision is to build our position as an innovator and leading player in the Molecular Imaging field. We aim to create value for patients and physicians by improving early detection and characterization of chronic and life-threatening diseases leading to better therapeutic outcomes and improved quality of life. For our approved PET tracer Neuraceq® (Florbetaben 18F) and our pipeline of tracers in clinical development we offer the following full-time position:
Main Tasks and responsibilities:
The candidate will join an interdisciplinary research and development group and participate in the development of innovative radiopharmaceuticals. The main goal of this position is to support the data management, statistical analysis, and regulatory submissions. The candidate will initially be responsible of supporting all CDISC standardization (SDTM/ADaM) and regulatory submission activities. In the future the candidate will progressively participate in other statistical-related activities such as CRF design, protocol review, development of statistical analysis plans, and statistical analysis.
Qualification and experience:
The position can be either based in our headquarters in Berlin or home-based in the European Union (EU). The development of the duties may require occasional travel to the headquarters in Berlin (Germany).
If you want to become part of an entrepreneurial team, assume a wide range of responsibilities and your experience fits the above description, please send us your complete application (Cover letter detailing your interest in this position including your past relevant research and work experience, CV) as a single pdf document to:
Annekathrin Kirchner/ Human Resources :- email@example.com
Life Molecular Imaging GmbH
Tegeler Str. 6-7
We are looking forward to receiving your application!
* The person counts, not the gender!
Life Molecular Imaging is committed to diversity, rejects discrimination and does not think in categories such as gender, ethnic origin, religion, disability, age or sexual identity.
Life Molecular Imaging GmbH is an Equal Opportunity Employer. We believe what we do and our culture of “More Than a Job. It’s Making Life Better” extends to creating a welcoming, safe, and inclusive work environment.
PRODUCT INDICATIONS AND USE: Neuraceq is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s Disease (AD) and other causes of cognitive decline. A negative Neuraceq scan indicates sparse to no neuritic plaques and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient’s cognitive impairment is due to AD. A positive Neuraceq scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD, but may also be present in patients with other types of neurologic conditions as well as older people with normal cognition. Neuraceq is an adjunct to other diagnostic evaluations.
Limitations: Limitations of Use
A positive Neuraceq scan does not establish the diagnosis of AD or any other cognitive disorder. The safety and effectiveness of Neuraceq have not been established for Predicting the development of dementia or other neurologic conditions or monitoring responses to therapies.
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
USE IN SPECIFIC POPULATIONS
A pharmacological overdose of Neuraceq is unlikely given the relatively low doses used for diagnostic purposes. In the event of administration of a radiation overdose with Neuraceq, the absorbed organ dose to the patient should be reduced by increasing elimination of the radionuclide from the body by inducing frequent micturition. Prior to Neuraceq administration, please read the full Prescribing Information for additional Important Safety Information.
SUSPECTED ADVERSE REACTIONS please report to: https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program